Accurate Reference-Free Somatic Variant-Calling by Integrating Genomic, Sequencing and Population Data
Authors:
- Ren X. SunRSRen X. Sun
- Christopher M. LalansinghCLChristopher M. Lalansingh
- Shadrielle Melijah G. EspirituSEShadrielle Melijah G. Espiritu
- Cindy Q. YaoCYCindy Q. Yao
- Takafumi N. YamaguchiTYTakafumi N. Yamaguchi
- Stephenie D. ProkopecSPStephenie D. Prokopec
- Lesia SzycaLSLesia Szyca
- Kathleen E. HoulahanKHKathleen E. Houlahan
- Lawrence E. HeislerLHLawrence E. Heisler
- Morgan BlackMBMorgan Black
- Constance H. LiCLConstance H. Li
- John W. BarrettJBJohn W. Barrett
Preprint
Abstract
The detection of somatic single nucleotide variants (SNVs) is critical in both research and clinical applications. Studies of human cancer typically use matched normal (reference) samples from a distant tissue to increase SNV prediction accuracy. This process both doubles sequencing costs and poses challenges when reference samples are not readily available, such as for many cell-lines. To address these challenges, we created S22S: an approach for the prediction of somatic mutations without need for matched reference tissue. S22S takes underlying sequence data, augments them with genomic background context and population frequency information, and classifies SNVs as somatic or non-somatic. We validated S22S using primary tumor/normal pairs from four tumor types, spanning two different sequencing technologies. S22S robustly identifies somatic SNVs, with the area under the precision recall curve reaching 0.97 in kidney clear cell carcinoma, comparable to the best tumor/normal analysis pipelines. S22S is freely available at http://labs.oicr.on.ca/Boutros-lab/software/s22s .Keywords
This publication has 47 references indexed in Scilit:
- Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detectionNature Methods, 2015
- Whole genomes redefine the mutational landscape of pancreatic cancerNature, 2015
- Comparison of somatic mutation calling methods in amplicon and whole exome sequence dataBMC Genomics, 2014
- Mutational landscape and significance across 12 major cancer typesNature, 2013
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- The landscape of cancer genes and mutational processes in breast cancerNature, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potencyJournal of Clinical Investigation, 2007